➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
McKinsey
AstraZeneca
Johnson and Johnson
Moodys

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 6,602,989

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,602,989
Title: Synthesis, characterization, and application of pyridylazo bioconjugates as diagnostic and therapeutic agents
Abstract:The detection of gallium in biological samples is required due to its role in the diagnosis of tumor and for possible treatment of malignancies. However, the use of purely instrumental techniques is unsuitable for detection of low levels of gallium in biological matrices. New protein conjugates have been synthesized based on 4-(2-pyridylazo) ligands. The conjugates detect gallium in biological matrices using a non antibody-based sandwich assay format. The recovery level is between 97-101.3 with a relative standard deviation of less than 5%. The assay results in a detection limit of 5.times.10.sup.-8 M and a remarkable selectivity for gallium(III) relative to other metals investigated. The new method provides adequate accuracy for gallium applicable for animal physiology and clinical toxicology.
Inventor(s): Sadik; Omowunmi A. (Vestal, NY), Xu; Hongwu (Binghamton, NY)
Assignee: The Research Foundation of State University of New York (Albany, NY)
Application Number:09/573,993
Patent Claims:see list of patent claims

Details for Patent 6,602,989

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Grifols Usa, Llc PLASBUMIN albumin (human) SOLUTION 101138 1 1994-09-26   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
Baxalta Us Inc. FLEXBUMIN albumin human INJECTION, SOLUTION 101452 1 2014-07-31   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
Csl Behring Ag ALBURX albumin (human) SOLUTION 102366 1 2009-01-06   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
Grifols Usa, Llc ALBUTEIN albumin (human) INJECTION, SOLUTION 102478 1 2019-12-15   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
Grifols Usa, Llc HUMAN ALBUMIN GRIFOLS albumin (human) SOLUTION 103352 1 2003-06-11   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
Csl Behring Llc ALBUMINAR-25 albumin (human) SOLUTION 103955 1 2009-01-06   Start Trial The Research Foundation of State University of New York (Albany, NY) 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Dow
Medtronic
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.